Interstitial lung diseases (ILDs) are a group of rare, complex disorders characterized by progressive fibrosis and inflammation of the lungs. ILDs encompass over 200 distinct types; patients affected by some forms currently face a median survival of only 3 to 5 years following diagnosis, highlighting an urgent need for innovative treatments.

Current IDL treatments are based on oral formulations, often with suboptimal efficacy and high toxicity levels, ultimately leading to therapy discontinuation in nearly 50% of patients. At A.D.A., we have developed a breakthrough inhalation therapy platform, leveraging multifunctional nanoparticles engineered to serve both as drug carriers and active therapeutic agents (“Drug AND Delivery”). These advanced nanoparticles can be used as standalone treatment, or in combination therapies encapsulating additional molecules to target multiple signalling pathways — a vital advantage for addressing the complex, multifactorial nature of interstitial lung diseases.